Actelion

CompanySwitzerland

Actelion develops one asset, in phase 3 (macitentan in pulmonary arterial hypertension). Mostly small molecule acting on EDNRA and EDNRB; based in Switzerland.

Assets
1
Furthest
Phase 3
Trials
3
Signals
0

Pipeline

1

  • macitentan

    Dual endothelin receptor antagonist (ETA and ETB)

    Phase 3Small moleculeEDNRAEDNRBpulmonary arterial hypertension

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Trials3
  • Similar companies2

Updated 7 Oct 2026 · 4 sources

Intelligence